Nurse Family Partnership: Comparing Costs per Family in Randomized Trials Versus Scale-Up
Access Status
Authors
Date
2015Type
Metadata
Show full item recordCitation
Source Title
ISSN
School
Collection
Abstract
The literature that addresses cost differences between randomized trials and full-scale repli- cations is quite sparse. This paper examines how costs differed among three randomized trials and six statewide scale-ups of nurse family partnership (NFP) intensive home visitation to low income first- time mothers. A literature review provided data on pertinent trials. At our request, six well-established programs reported their total expenditures. We adjusted the costs to national prices based on mean hourly wages for registered nurses and then inflated them to 2010 dollars. A centralized data system provided utilization. Replications had fewer home visits per family than trials (25 vs. 31, p = .05), lower costs per client ($8860 vs. $12,398, p = .01), and lower costs per visit ($354 vs. $400, p = .30). Sample size limited the significance of these differences. In this type of labor intensive program, costs probably were lower in scale-up than in randomized trials. Key cost drivers were attrition and the stable caseload size possible in an ongoing program. Our estimates reveal awide variation in cost per visit across six state programs, which suggests that those planning replications should not expect a simple rule to guide cost estimations for scale-ups. Nevertheless, NFP replications probably achieved some economies of scale.
Related items
Showing items related by title, author, creator and subject.
-
Miller, Ted; Hendrie, Delia (2015)© 2015, Springer Science+Business Media New York. The literature that addresses cost differences between randomized trials and full-scale replications is quite sparse. This paper examines how costs differed among three ...
-
Munns, Ailsa; Watts, R.; Hegney, D.; Walker, R. (2016)BACKGROUND: Designing child and family health services to meet the diverse needs of contemporary families is intended to minimize impacts of early disadvantage and subsequent lifelong health and social issues. Innovative ...
-
Lenton, Simon; Dietze, P.; Olsen, A.; Wiggins, N.; McDonald, D.; Fowler, C. (2014)Issue. Since the mid-1990s, there have been calls to make naloxone, a prescription-only medicine in many countries, available to heroin and other opioid users and their peers and family members to prevent overdose deaths. ...